Rotavirus Vaccine

Pre-clinicalTerminated

3 views this week 0 watching💤 Quiet

Interest: 18/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pediatric Gastroenteritis

Conditions

Pediatric Gastroenteritis

Trial Timeline

Aug 1, 2010 → Nov 1, 2011

NCT ID

NCT01195844

About Rotavirus Vaccine

Rotavirus Vaccine is a pre-clinical stage product being developed by Merck for Pediatric Gastroenteritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01195844. Target conditions include Pediatric Gastroenteritis.

What happened to similar drugs?

3 of 19 similar drugs in Pediatric Gastroenteritis were approved

Approved (3) Terminated (0) Active (16)

✅Boosted AtazanavirBristol Myers SquibbApproved

✅Atazanavir + RitonavirBristol Myers SquibbApproved

✅IgPro10CSLApproved

🔄candsartan cilexetilAstraZenecaPhase 3

🔄basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroidsNovartisPhase 3

🔄VAL489 + VAL489 matching placeboNovartisPhase 3

🔄Entecavir + Lamivudine + Pegylated Interferon Alfa-2ARochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05212935	Pre-clinical	UNKNOWN	May 1, 2022	Apr 1, 2023	Vaccination
NCT01195844	Pre-clinical	Terminated	Aug 1, 2010	Nov 1, 2011	Pediatric Gastroenteritis

Competing Products

20 competing products in Pediatric Gastroenteritis

See all competitors

Product	Company	Stage	Hype Score
Ramucirumab	Eli Lilly	Phase 1	29
erlotinib + etoposide	Astellas Pharma	Phase 2	27
Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine	Sun Pharmaceutical	Phase 1	33
Perampanel Oral Suspension + Perampanel Tablet	Eisai	Phase 2	42
Eribulin Mesylate	Eisai	Phase 1	29
Decitabine + Decitabine	Eisai	Phase 2	27
Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily	Sumitomo Pharma	Phase 1	29
Remimazolam Tosilate for injection + Propofol Injection	Jiangsu Hengrui Medicine	Phase 2/3	45
Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid	AstraZeneca	Phase 2/3	38
candsartan cilexetil	AstraZeneca	Phase 3	40
Durvalumab / Tremelimumab Combination Therapy	AstraZeneca	Phase 1/2	36
basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids	Novartis	Phase 3	40
VAL489 + VAL489 matching placebo	Novartis	Phase 3	40
LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696	Novartis	Phase 2/3	38
Everolimus	Novartis	Phase 2	35
Corticosteroids + Cyclosporine + mycophenolate mofetil	Roche	Phase 2	27
Entecavir + Lamivudine + Pegylated Interferon Alfa-2A	Roche	Phase 3	40
Blinatumomab for Injection	Amgen	Phase 1	25
Etanercept	Amgen	Phase 3	40
Denosumab	Amgen	Phase 3	40